Reading the tape
NASDAQ: ALGS
Aligos Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$39.30M
52w High
$13.69
52w Low
$4.20
P/E
-2.73
Volume
74.71K
Outstanding Shares
6.19M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 25.74%Revenue (TTM): -44.59%FCF (TTM): -2.56%P/S: 46th pct
What changed
The stock rose 25.74% over the last year. Revenue declined 44.59% over the trailing twelve months. Operating margin moved from -2,259.92% to -4,024.93%. Free cash flow declined 2.56% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -4,024.93%. A decisive move in revenue — currently down 44.59% — would be the clearest signal to resolve the ambiguity.
Company profile
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.
CEOLawrence Blatt
SectorHealthcare
IndustryBiotechnology
Employees70
IPO dateOct 16, 2020
Valuation
Forward P/E—
EV/EBITDA-0.91
Enterprise value$79.07M
Stock splits
Aug 19, 2024↓ Reverse
Every 25 shares became 1
Profitability & growth
Revenue growth-73.13%
Gross margin76.4%▼42.54%vs FY2024
Operating margin-4,024.93%▼78.10%vs FY2024
ROE-45.18%▼109.98%vs FY2024
Analyst consensus
RatingBuy
Target price$20.00▲214.96%
3
Buy
2
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$2.29 · Revenue est $250K
View